Full-Time

Scientist I/II

Human Ex Vivo Systems

Confirmed live in the last 24 hours

Gordian Biotechnology

Gordian Biotechnology

11-50 employees

Biotech startup focused on age-related disease therapies

Biotechnology
Healthcare

Compensation Overview

$115k - $150kAnnually

Junior, Mid

San Bruno, CA, USA

The job is onsite in South San Francisco, CA.

Category
Lab & Research
Life Sciences
Required Skills
Data Analysis

You match the following Gordian Biotechnology's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Experience with complex/fragile culture systems, like primary patient cells or complex differentiation protocols
  • Experienced with RT-qPCR and enzymatic protein readouts, including statistical analysis of multi-cohort experiments
  • Experience managing and collaborating on time-sensitive projects involving large numbers of experimental conditions, often with overlapping timecourses
Responsibilities
  • Design and execute experiments using patient samples to validate and optimize hits from in vivo pooled screens in osteoarthritic horses
  • Manage all scientific and logistical aspects of ex vivo validation experiments
  • Plan and execute validation projects testing therapeutic efficacy across multiple human donor samples
  • Analyze data and report findings from experiments
Desired Qualifications
  • Experience with GAG assays, inflammatory protein panels, or histological assessment of cartilage
  • Bonus points for experience working on drug testing, ideally in an industry setting, for direct experience with osteoarthritis or relevant areas of biology (inflammation, tissue regeneration/fibrosis, pain)
Gordian Biotechnology

Gordian Biotechnology

View

Gordian Biotechnology focuses on developing treatments for age-related diseases through drug discovery. The company uses advanced technologies to create models that accurately reflect the biological processes of aging, which helps in testing therapies in conditions similar to those in humans. This method increases the chances of success in clinical trials. Gordian Bio primarily collaborates with pharmaceutical companies, research institutions, and healthcare providers, generating revenue through partnerships and licensing agreements. Their goal is to extend healthy human lifespan by addressing the underlying causes of age-related diseases. They utilize animal models, like fruit flies, to study aging and test new therapies, which enhances the reliability of their research. The team consists of experts in gene therapy and genome engineering, and their work has been recognized at major industry conferences.

Company Size

11-50

Company Stage

Seed

Total Funding

$58.4M

Headquarters

South San Francisco, California

Founded

1990

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased interest in personalized medicine aligns with Gordian's screening capabilities.
  • Growing focus on longevity research attracts investment, benefiting Gordian's funding opportunities.
  • Collaborations with academic institutions offer research partnerships and scientific insights.

What critics are saying

  • Reliance on animal models may face ethical scrutiny and regulatory challenges.
  • Dependence on advanced technologies exposes Gordian to risks of obsolescence and supply chain issues.
  • Niche focus on age-related diseases might limit market opportunities and funding availability.

What makes Gordian Biotechnology unique

  • Gordian Bio uses 'patient avatars' for drug testing, mimicking human conditions closely.
  • Their high-throughput in vivo screening platform tests hundreds of gene therapies simultaneously.
  • Gordian Bio focuses on age-related diseases, a niche yet critical segment in biotech.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Remote Work Options

Meal Benefits

Gym Membership

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
Longevity Technology
Apr 26th, 2024
Gordian launches with $60m and platform that predicts outcomes in age-related diseases

High-throughput in vivo screening platform can test hundreds of gene therapies simultaneously in animals closely mirroring human biology.

Longevity Technology
Apr 26th, 2024
Gordian Launches with $60M for Gene Therapy

Gordian Biotechnology launched with $60m in venture capital, introducing a high-throughput in vivo screening platform for age-related diseases. Using "patient avatars" like horses and monkeys, the platform tests hundreds of gene therapies simultaneously, achieving 80% predictive accuracy in proof-of-concept experiments. This method could significantly streamline drug discovery and development for age-related conditions.

PR Newswire
Apr 26th, 2024
Gordian Biotechnology Introduces High-Throughput In Vivo Screening Platform To Discover Therapies And Better Predict Human Outcomes For Age-Related Diseases

Gordian's Osteoarthritis (OA) program has screened hundreds of therapies in horses that acquired OA naturally and advanced dozens of therapies into human ex vivo validation studies. The results of these ex vivo studies matched screen predictions with 80% accuracy, and several hits progressed to additional testing and optimization. Gordian presented these findings at the Osteoarthritis Research Society International (OARSI) World Congress last week.In proof of concept experiments during initial development, Gordian introduced a pooled library of 50 gene therapies into a mouse model of metabolic-associated steatohepatitis (MASH). The therapies were evaluated using the company's proprietary in vivo screening platform, which successfully recapitulated 13 out of 16 clinical outcomes for targets where clinical data exists.Today, Gordian is completing in vivo screens of thousands of novel single and multi-target therapies across four indications in highly representative animal models across multiple species."Gordian leverages recent advancements in single-cell sequencing and gene therapy to discover and predict what drugs will be successful in a way that would have been inconceivable just five years ago," said co-founder and CEO Francisco LePort. "Our ultimate goal is to help people wake up every day, more capable than the one before."The first and only platform of its kindScreening in vivo lets Gordian run the equivalent of hundreds of preclinical experiments in a matter of months and at a small fraction of the cost of traditional preclinical studies. Thus, enormous amounts of in vivo data are obtained at the beginning of the discovery process in animal models that would otherwise be impractical to use, allowing only the most efficacious therapeutics to move into development and clinical trials.The Gordian platform consists of three proprietary components working in concert:Patient Avatars™ are animal models with biology more representative of human patients than those typically used, such as horses for OA and monkeys for MASH

BioSpace
Apr 26th, 2024
Gordian Biotechnology Introduces High-Throughput In Vivo Screening Platform to Discover Therapies and Better Predict Human Outcomes for Age-Related Diseases

Gordian Biotechnology introduces high-throughput in vivo screening platform to discover therapies and better predict human outcomes for age-related diseases.